Healthy volunteers test new Blood-Clot drug in Early-Stage trial
NCT ID NCT07133191
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 41 times
Summary
This completed Phase 1 trial tested a single 16 mg dose of selatogrel, an injectable drug that affects blood clotting, in 32 healthy adults (16 Japanese and 16 Caucasian). The goal was to see how the body absorbs and processes the drug and how well it is tolerated. This study was for research only and did not aim to treat any medical condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CenExel ACT (Anaheim Clinical Trials)
Anaheim, California, 92801, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selatogrel (a reversible P2Y12 receptor antagonist given as a single injection)
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.